Beyond Biotech - the podcast from Labiotech
Beyond Biotech podcast 49
1:24 Labiotech news
3:40 BC Platforms
A conversation about precision medicine with Tero Silvola, CEO at BC Platforms. We also discuss the acquisition of 4Pharma.
The acquisition expands BCP’s global service offering for accelerating the translation of innovations into clinical practice. In addition, 4Pharma customers will benefit from additional services in the field of RWD through the BC Platform technology.
4Pharma (HQ Turku, Finland and Lund, Sweden) was founded more than 20 years ago, and has collaborations with around 70 clients in the Nordics, Central Europe, and the U.S. The company has developed expertise in a range of therapeutic areas including oncology, neurology, ophthalmology, musculoskeletal, respiratory diseases, infectious diseases, and gynecology.
The company provides medical research services in several areas: high-quality and cost-effective solutions for the management and delivery of clinical trial data, including real world data; medical writing; patient safety data collection, analysis, and reporting including data visualization; trial design & interpretation; health technology assessment; global regulatory submissions to the FDA (U.S.), EMA (Europe) and PMDA (Japan); and risk-based patient monitoring. With this acquisition BCP bolsters its capabilities in these areas for drug development and clinical research, which further diversifies its service portfolio for pharma and biotech clients.
Tero Silvola, CEO at BC Platforms, said: “This exciting acquisition of the excellent 4Pharma brings impressive healthcare data intelligence expertise. It aligns with our vision to build a world leading analytics platform to enable the pharmaceutical industry’s advancement of precision medicine, improving the efficiency of drug development and patient outcomes. This expands our service offering to healthcare and lifesciences customers, as well as connecting data partners in a global, interoperable federated network. We combine omics and clinical data assets around the world, without compromising data privacy and security. This enables our customers to conduct novel research and discover fascinating new insights to advance healthcare which are fundamental to helping patients receive better treatments and care.”
1:24 Labiotech news
3:40 BC Platforms
A conversation about precision medicine with Tero Silvola, CEO at BC Platforms. We also discuss the acquisition of 4Pharma.
The acquisition expands BCP’s global service offering for accelerating the translation of innovations into clinical practice. In addition, 4Pharma customers will benefit from additional services in the field of RWD through the BC Platform technology.
4Pharma (HQ Turku, Finland and Lund, Sweden) was founded more than 20 years ago, and has collaborations with around 70 clients in the Nordics, Central Europe, and the U.S. The company has developed expertise in a range of therapeutic areas including oncology, neurology, ophthalmology, musculoskeletal, respiratory diseases, infectious diseases, and gynecology.
The company provides medical research services in several areas: high-quality and cost-effective solutions for the management and delivery of clinical trial data, including real world data; medical writing; patient safety data collection, analysis, and reporting including data visualization; trial design & interpretation; health technology assessment; global regulatory submissions to the FDA (U.S.), EMA (Europe) and PMDA (Japan); and risk-based patient monitoring. With this acquisition BCP bolsters its capabilities in these areas for drug development and clinical research, which further diversifies its service portfolio for pharma and biotech clients.
Tero Silvola, CEO at BC Platforms, said: “This exciting acquisition of the excellent 4Pharma brings impressive healthcare data intelligence expertise. It aligns with our vision to build a world leading analytics platform to enable the pharmaceutical industry’s advancement of precision medicine, improving the efficiency of drug development and patient outcomes. This expands our service offering to healthcare and lifesciences customers, as well as connecting data partners in a global, interoperable federated network. We combine omics and clinical data assets around the world, without compromising data privacy and security. This enables our customers to conduct novel research and discover fascinating new insights to advance healthcare which are fundamental to helping patients receive better treatments and care.”